ArticleBlood advances2020

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.

Kirk E Cahill et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.